a Division of Hematology , University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria , Varese , Italy.
b Department of Hematology-Oncology, Fondazione IRCCS Policlinico San Matteo & Department of Molecular Medicine , University of Pavia , Pavia , Italy.
Expert Rev Hematol. 2016 Aug;9(8):767-80. doi: 10.1080/17474086.2016.1205949. Epub 2016 Jul 14.
Brentuximab vedotin (BV) is a potent anti-CD30 antibody drug conjugate (ADC) that has been approved in relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT) and anaplastic large-cell lymphoma (ALCL). Beyond these consolidated indications, BV has been tested in a number of different settings with promising results, leading for example to the recent approval as a consolidation after ASCT in high-risk HL patients.
Main emerging areas of clinical investigation of BV include the use as a single-agent or in combination with bendamustine in first-salvage therapy of HL (bridge to ASCT), in the frontline setting in combination with AVD chemotherapy in HL and with CHP in ALCL, in relapsed or refractory cutaneous T-cell lymphomas and finally in diffuse large B-cell lymphomas (DLBCL) expressing CD30. Moreover, many new ADCs are currently under clinical evaluation, as for example the anti-CD79A polatuzumab vedotin in DLBCL. Expert commentary: In few years BV changed the therapeutic scenario of relapsed or refractory HL and ALCL and is rapidly moving toward first-line approval in combination with standard chemotherapy if ongoing randomized trials will demonstrate improved results. Combination strategies with bendamustine in first-salvage HL and with R-CHP in first-line DLBCL appear very promising.
本妥昔单抗维布妥昔单抗（BV）是一种强效的抗 CD30 抗体药物偶联物（ADC），在自体干细胞移植（ASCT）和间变性大细胞淋巴瘤（ALCL）后复发或难治性霍奇金淋巴瘤（HL）中已获得批准。除了这些巩固的适应症外，BV 已经在许多不同的环境中进行了测试，结果令人鼓舞，例如最近在高危 HL 患者 ASCT 后巩固治疗中获得批准。
BV 临床研究的主要新兴领域包括作为单一药物或与苯达莫司汀联合用于 HL 的一线挽救治疗（桥接 ASCT），在 HL 中与 AVD 化疗联合用于一线治疗，与 CHP 联合用于 ALCL，在复发或难治性皮肤 T 细胞淋巴瘤中，最后在表达 CD30 的弥漫性大 B 细胞淋巴瘤（DLBCL）中。此外，许多新的 ADC 目前正在临床评估中，例如在 DLBCL 中的抗 CD79A 波替单抗维布妥昔单抗。
在短短几年内，BV 改变了复发或难治性 HL 和 ALCL 的治疗格局，如果正在进行的随机试验显示出改善的结果，它将迅速在联合标准化疗的一线治疗中获得批准。在一线挽救性 HL 中与苯达莫司汀联合以及在一线 DLBCL 中与 R-CHP 联合的策略似乎非常有前途。
